Phase II study of irinotecan, leucovorin, 5-fluorouracil (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer.

Trial Profile

Phase II study of irinotecan, leucovorin, 5-fluorouracil (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Oct 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 18 Apr 2011 Actual end date (March 2011) added as reported by ClinicalTrials.gov.
    • 18 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top